Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer

BACKGROUND: The updated randomised phase 2/3 FIRIS study demonstrated the noninferiority of IRIS (irinotecan and S-1) to FOLFIRI (irinotecan, folinic acid, and 5-FU) for metastatic colorectal cancer. Meanwhile, in the subset analysis including patients who previously have undergone oxaliplatin-conta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baba, H, Watanabe, M, Okabe, H, Miyamoto, Y, Sakamoto, Y, Baba, Y, Iwatsuki, M, Chikamoto, A, Beppu, T
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3516688/
https://ncbi.nlm.nih.gov/pubmed/23169295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.502
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados